- Home
- ESS vs BBIO Comparison
ESS vs BBIO Comparison
Compare ESS & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ESS | BBIO |
|---|---|---|
| Founded | 1971 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.3B | 15.3B |
| IPO Year | 1996 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ESS | BBIO |
|---|---|---|
| Price | $254.09 | $73.95 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 16 | 23 |
| Target Price | ★ $282.30 | $82.26 |
| AVG Volume (30 Days) | 425.6K | ★ 2.8M |
| Earning Date | 01-01-0001 | 05-22-2026 |
| Dividend Yield | ★ 4.03% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 10.40 | N/A |
| Revenue | ★ $1,887,345,000.00 | $502,076,000.00 |
| Revenue This Year | $1.84 | $88.86 |
| Revenue Next Year | $3.30 | $74.11 |
| P/E Ratio | $24.57 | ★ N/A |
| Revenue Growth | 6.36 | ★ 126.26 |
| 52 Week Low | $243.25 | $28.33 |
| 52 Week High | $310.10 | $84.94 |
Technical Indicators
Market Signals| Indicator | ESS | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 47.93 | 58.38 |
| Support Level | $249.42 | $70.65 |
| Resistance Level | $264.12 | $79.56 |
| Average True Range (ATR) | 5.28 | 3.35 |
| MACD | -0.11 | 0.42 |
| Stochastic Oscillator | 37.27 | 86.03 |
Price Performance
Historical ComparisonAbout ESS Essex Property Trust Inc.
Essex Property Trust owns a portfolio of 258 apartment communities with over 62,000 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.